We've upgraded AI Tools on TaxTMI with two powerful modes:
1. Basic • Quick overview summary answering your query with references• Category-wise results to explore all relevant documents on TaxTMI
2. Advanced • Includes everything in Basic • Detailed report covering: - Overview Summary - Governing Provisions [Acts, Notifications, Circulars] - Relevant Case Laws - Tariff / Classification / HSN - Expert views from TaxTMI - Practical Guidance with immediate steps and dispute strategy
• Also highlights how each document is relevant to your query, helping you quickly understand key insights without reading the full text.Help Us Improve - by giving the rating with each AI Result:
Tribunal orders reassessment for medicament valuation, highlights legal principles. The Tribunal directed a reconsideration by the adjudicating authority in line with the Apex Court's decision in CCE vs. Cosme Farma Laboratories Ltd, ...
Cases where this provision is explicitly mentioned in the judgment/order text; may not be exhaustive. To view the complete list of cases mentioning this section, Click here.
Provisions expressly mentioned in the judgment/order text.
Tribunal orders reassessment for medicament valuation, highlights legal principles.
The Tribunal directed a reconsideration by the adjudicating authority in line with the Apex Court's decision in CCE vs. Cosme Farma Laboratories Ltd, emphasizing assessable value components for the valuation of P or P medicaments for Central Excise duty calculation during a specific period. The appellant was allowed to submit a Cost Accountant's certificate for consideration, leading to the appeal being disposed of with an emphasis on adherence to legal principles and natural justice in the reassessment process.
Issues: Valuation of P or P medicaments for Central Excise duty calculation during a specific period.
The judgment pertains to an appeal against an Order-in-Appeal dated 31.03.2008 concerning the valuation of P or P medicaments for Central Excise duty calculation between 21.05.2004 to 08.01.2005. The appellant, a loan licensee of a company manufacturing the medicaments, faced challenges from the revenue regarding the valuation method used for duty discharge. The revenue contested the appellant's deduction of discounts offered by the manufacturer, arguing that evidence of passing on discounts to customers was lacking. The adjudicating authority upheld the demands, interest, and penalties imposed. The first appellate authority supported the decision but outlined the correct method for calculating Central Excise duty based on raw material value, job work, manufacturing profit, and expenses. The appellant cited a Supreme Court judgment in CCE vs. Cosme Farma Laboratories Ltd, claiming excess duty payment based on the Apex Court's decision. The departmental representative echoed the first appellate authority's findings. The Tribunal noted the settled valuation principles for medicaments manufactured by a loan licensee/job worker as per the Apex Court's ruling in Cosme Farma Laboratories Ltd, emphasizing the assessable value components. The Tribunal directed a reconsideration by the adjudicating authority in line with the Apex Court's decision, allowing the appellant to submit a Cost Accountant's certificate for consideration. The appeal was disposed of accordingly, emphasizing adherence to legal principles and natural justice in the reassessment process.
Full Summary is available for active users!
Note: It is a system-generated summary and is for quick reference only.